Find the next great radioligand target before your competitors do.
Nuclens reads your target thesis in plain English, evaluates a catalog of oncology targets against the constraints that actually matter for radioligand therapy, and returns a ranked, fully-sourced shortlist — in minutes, not months. Every number traces back to a public database you already trust.
Rank targets free. Pay only when you generate a full decision report.
A glimpse of the workflow.
An illustrative preview — real targets, real sourced data. Your results are driven by your own criteria.
Click any target to expand its scorecard
The industry's biggest bets — RayzeBio ($4.1B), Fusion ($2.4B), Point Biopharma — were all races to the same scarce resource: the right target.
Approved franchises and billion-dollar acquisitions have made target selection the bottleneck everyone is fighting over.
Localization, dosimetry-organ expression, tumor specificity, competition — pulled by hand, one tab at a time.
Every quarter spent hunting targets is a quarter a faster competitor spends validating them.
A radiopharma-specific reasoning engine — not a generic database.
General target-ID tools weren't built for radioligand therapy. Nuclens is. It scores every candidate on the constraints that decide whether a target can actually become a radioligand.
Ask in plain English
“Cell-surface target, low kidney expression, high tumor-to-background in pancreatic cancer.” Nuclens parses the intent — including radiopharma domain rules like alpha-therapy marrow toxicity — and filters the catalog deterministically before it ever ranks.
Scored on what matters for RLT
Cell-surface access, dose-limiting organ expression, tumor-to-kidney ratio, internalization, shedding, competitive landscape — each candidate gets a transparent scorecard, not a black-box number.
Every claim is traceable
Localization from UniProt. Expression from the Human Protein Atlas. Stage from ClinicalTrials.gov. Each data point carries its source · version · value — defensible in a program review, not just a demo.
Decision-grade reports in one click
Generate a structured target brief — biology, clinical evidence, radioligand context, safety, competition, open questions — grounded in your data and current literature. A day of desk research, on demand.
Thesis in. Ranked, sourced shortlist out.
Describe your target profile
Type the biology, indication, modality, and safety constraints in your own words — or use the hard filters.
The engine filters, then ranks
Deterministic filters fix the candidate pool; a radiopharma-tuned model scores each one across six weighted dimensions.
Review, trace, and report
Open any target's sources, compare the shortlist, and generate a full decision report when you're ready to go deep.
Trust comes from transparency, not confidence.
We'd rather show you the evidence and its limits than a number you can't check. That's what makes a tool safe to base a program decision on.
Sourced, versioned, verifiable
No orphan claims. Every value shown is attributed to a specific public dataset and release, so your team can open the primary source in one click.
Honest about its limits
Nuclens is a first-pass triage layer — it compresses weeks of screening into minutes. It does not replace wet-lab internalization assays, clinical dosimetry, or freedom-to-operate. AI-extracted literature is flagged for verification.
Reproducible by design
Hard filters run deterministically, so the same criteria return the same candidate pool every time — the reasoning layer only ranks within it.
One workflow, three decisions it accelerates.
See the whole radioligand target landscape in an afternoon, not a quarter. Prioritize pipeline bets with the evidence attached and the reasoning you can defend to a board.
Skip the tab-by-tab database grind. Spend your hours validating the shortlist instead of assembling it — with every source one click away.
Map competition and white space fast. Walk into partnering conversations knowing which targets are crowded and which are genuinely open.
The next PSMA is in a database right now.
Someone is going to find it. Give your team the AI layer that gets there first — start free, and only pay when a target is worth a full report.